PD-L1 inhibits acute and chronic pain by suppressing nociceptive neuron activity via PD-1

被引:0
|
作者
Gang Chen
Yong Ho Kim
Hui Li
Hao Luo
Da-Lu Liu
Zhi-Jun Zhang
Mark Lay
Wonseok Chang
Yu-Qiu Zhang
Ru-Rong Ji
机构
[1] Duke University Medical Center,Department of Anesthesiology
[2] Key Laboratory of Neuroregeneration of Jiangsu and Ministry of Education,Department of Physiology
[3] Co-Innovation Center of Neuroregeneration,Department of Neurobiology
[4] Nantong University,undefined
[5] College of Medicine,undefined
[6] Gachon University,undefined
[7] Institute of Neurobiology,undefined
[8] Institutes of Brain Science and State Key Laboratory of Medical Neurobiology,undefined
[9] Collaborative Innovation Center for Brain Science,undefined
[10] Fudan University,undefined
[11] Duke University Medical Center,undefined
来源
Nature Neuroscience | 2017年 / 20卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
The authors identify programmed cell death ligand-1 (PD-L1), an immunity suppressor produced by cancer cells, as a new pain inhibitor and a neuromodulator. They report that PD-L1 is produced by melanoma and normal neural tissues and that it inhibits acute and chronic pain. Via activation of PD-1, its receptor, PD-L1 decreases the excitability of nociceptive neurons in mouse and human dorsal root ganglia.
引用
收藏
页码:917 / 926
页数:9
相关论文
共 50 条
  • [31] PD-1/PD-L1 expression in extramedullary lesions of acute myeloid leukemia
    Meleveedu, Kapil S.
    Chen, Dong
    Nadiminti, Kalyan
    Sidiqi, Hasib
    Khan, Shakila
    Alkhateeb, Hassan
    Shah, Mithun V.
    Patnaik, Mrinal
    Hogan, William J.
    Begna, Kebede
    Litzow, Mark
    LEUKEMIA & LYMPHOMA, 2021, 62 (03) : 764 - 767
  • [32] Determination of PD-L1 positive CETCs as a biomarker for PD-1/PD-L1 treatment monitoring
    Pizon, M.
    Schott, D.
    Pachmann, U.
    Pachmann, K.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 89 - 89
  • [33] The PD-1/PD-L1 Pathway in Human Pathology
    Saresella, M.
    Rainone, V.
    Al-Daghri, N. M.
    Clerici, M.
    Trabattoni, D.
    CURRENT MOLECULAR MEDICINE, 2012, 12 (03) : 259 - 267
  • [34] PD-1/PD-L1 as a prognostic factor in leukemia
    Hadi Rezaeeyan
    Seyedeh Nafiseh Hassani
    Mojgan Barati
    Mohammad Shahjahani
    Najmaldin Saki
    Journal of Hematopathology, 2017, 10 : 17 - 24
  • [35] PD-1/PD-L1 Axis in Lung Cancer
    Santini, Fernando C.
    Hellmann, Matthew D.
    CANCER JOURNAL, 2018, 24 (01): : 15 - 19
  • [36] Expression of PD-L1 and PD-1 in Cutaneous Warts
    Yu, Wesley
    Berger, Timothy
    Laszik, G. Zoltan
    North, Jeffrey
    Cohen, Jarish
    LABORATORY INVESTIGATION, 2019, 99
  • [37] The PD-1:PD-L1 axis in Inflammatory Arthritis
    Mary Canavan
    Achilleas Floudas
    Douglas J. Veale
    Ursula Fearon
    BMC Rheumatology, 5
  • [38] Regulatory mechanisms of PD-1/PD-L1 in cancers
    Lin, Xin
    Kang, Kuan
    Chen, Pan
    Zeng, Zhaoyang
    Li, Guiyuan
    Xiong, Wei
    Yi, Mei
    Xiang, Bo
    MOLECULAR CANCER, 2024, 23 (01)
  • [39] Toxicities Associated With PD-1/PD-L1 Blockade
    Wang, Daniel Y.
    Johnson, Douglas B.
    Davis, Elizabeth J.
    CANCER JOURNAL, 2018, 24 (01): : 36 - 40
  • [40] Biomarkers of response to PD-1/PD-L1 inhibition
    Vareki, Saman Maleki
    Garrigos, Carmen
    Duran, Ignacio
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2017, 116 : 116 - 124